Earnings$GILD10:10 AM ET

Gilead Q3 sales beat estimates, HIV and Trodelvy drive 13% growth, stock hits record high

By BORSA NewsroomPublished Oct 30, 2026, 10:10 AM EDTUpdated Oct 30, 2026, 10:19 AM EDT

Gilead Sciences Q3 sales rose 13% to $8.3B, beating the $7.81B consensus. Adjusted EPS of $2.55 topped $2.19. HIV revenue grew 18%, Trodelvy beat at $506M. FY sales guidance raised to $31.1-31.3B. Stock +4% to record $172.03.

Sentimentbullish 85

Strongly bullish · 85 of 100

Impact80

high · market-wide

Confidence90%

high confidence · single wire

Eventdeveloping

v1 · alerted to followers

WHAT WE KNOW

Q3 sales $8.3B vs $7.81B est
Adj EPS $2.55 vs $2.19 est